Takle Eye Group is proud to present our newest procedure for patients who have cataracts and are also managing glaucoma. iStent® Trabecular Micro-Bypass is the first microinvasive glaucoma surgery (MIGS) device to safely reduce pressure in the eye by creating a permanent opening in the drainage network around the eye (called the trabecular meshwork).
The iStent® is the smallest ever FDA-approved medical device. It’s a snorkel-like tube that’s inserted into the trabecular meshwork during cataract surgery. No additional procedure is necessary. Once inserted, iStent® helps manage the flow of aqueous humor – the fluid in your eye – so that excess pressure in the eye is reduced and the danger of permanent damage is lessened.
iStent® may also decrease the need for some glaucoma medications prescribed to you, though this is at the discretion of your doctor.
If you have glaucoma, are planning for cataract surgery, and would like to discuss iStent® as a potential treatment option, contact us for a consultation at http://www.takleeye.com/contact-us/ or by calling 770-228-3836.
INDICATION FOR USE
The iStent® Trabecular Micro-Bypass Stent (Models GTS100R and GTS100L) is indicated for use in conjunction with cataract surgery for the reduction of intraocular pressure (IOP) in adult patients with mild to moderate open-angle glaucoma currently treated with ocular hypotensive medication.
The iStent is contraindicated in eyes with primary or secondary angle closure glaucoma, including neovascular glaucoma, as well as in patients with retrobulbar tumor, thyroid eye disease, Sturge-Weber Syndrome or any other type of condition that may cause elevated episcleral venous pressure.
Gonioscopy should be performed prior to surgery to exclude PAS, rubeosis, and other angle abnormalities or conditions that would prohibit adequate visualization of the angle that could lead to improper placement of the stent and pose a hazard. The iStent is MR-Conditional meaning that the device is safe for use in a specified MR environment under specified conditions, please see label for details.
The surgeon should monitor the patient postoperatively for proper maintenance of intraocular pressure. The safety and effectiveness of the iStent has not been established as an alternative to the primary treatment of glaucoma with medications, in children, in eyes with significant prior trauma, chronic inflammation, or an abnormal anterior segment, in pseudophakic patients with glaucoma, in patients with pseudoexfoliative glaucoma, pigmentary, and uveitic glaucoma, in patients with unmedicated IOP less than 22 mmHg or greater than 36 mmHg after ?washout? of medications, or in patients with prior glaucoma surgery of any type including argon laser trabeculoplasty, for implantation of more than a single stent, after complications during cataract surgery, and when implantation has been without concomitant cataract surgery with IOL implantation for visually significant cataract.
The most common post-operative adverse events reported in the randomized pivotal trial included early post-operative corneal edema (8%), BCVA loss of = 1 line at or after the 3 month visit (7%), posterior capsular opacification (6%), stent obstruction (4%) early post-operative anterior chamber cells (3%), and early post-operative corneal abrasion (3%). Please refer to Directions for Use for additional adverse event information.
Federal law restricts this device to sale by, or on the order of, a physician. Please reference the Directions for Use labeling for a complete list of contraindications, warnings, precautions, and adverse events.